CN110590931B - Method for removing and/or inactivating virus in recombinant human thrombopoietin stock solution - Google Patents
Method for removing and/or inactivating virus in recombinant human thrombopoietin stock solution Download PDFInfo
- Publication number
- CN110590931B CN110590931B CN201910837015.6A CN201910837015A CN110590931B CN 110590931 B CN110590931 B CN 110590931B CN 201910837015 A CN201910837015 A CN 201910837015A CN 110590931 B CN110590931 B CN 110590931B
- Authority
- CN
- China
- Prior art keywords
- inactivation
- fermentation liquor
- recombinant human
- viruses
- inactivating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 241000700605 Viruses Species 0.000 title claims abstract description 69
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 21
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 title claims abstract description 15
- 239000011550 stock solution Substances 0.000 title claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims abstract description 35
- 230000004151 fermentation Effects 0.000 claims abstract description 35
- 239000012528 membrane Substances 0.000 claims abstract description 25
- 238000001914 filtration Methods 0.000 claims abstract description 21
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 239000002114 nanocomposite Substances 0.000 claims abstract description 3
- 230000001361 thrombopoietic effect Effects 0.000 claims abstract description 3
- 230000002779 inactivation Effects 0.000 claims description 81
- 230000002209 hydrophobic effect Effects 0.000 claims description 25
- 238000004587 chromatography analysis Methods 0.000 claims description 24
- 238000005571 anion exchange chromatography Methods 0.000 claims description 19
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 12
- 238000005277 cation exchange chromatography Methods 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 5
- 239000013621 viresolve pro solution Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 230000004952 protein activity Effects 0.000 abstract description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 238000011068 loading method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 125000003473 lipid group Chemical group 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000001728 nano-filtration Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000000937 inactivator Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PRGXFAWAMOFULD-UHFFFAOYSA-N 2-(methylamino)-1-(2-methylphenyl)propan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1C PRGXFAWAMOFULD-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical group [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a method for removing and/or inactivating viruses in a recombinant human thrombopoietin stock solution, which comprises the following steps: inactivating virus by using a fermentation liquor of the recombinant human thrombopoietic factor by using an S/D method; and filtering the purified fermentation broth using a nanomembrane to remove viruses. The method according to the invention comprises the following steps: 1) Culturing rh-TPO engineering cells to obtain fermentation liquor; 2) Inactivating viruses of the fermentation liquor by using an S/D method; 3) Purifying the fermentation liquor inactivated by an S/D method; 4) Filtering the purified fermentation liquor by using a nano membrane to obtain the nano-composite. The method of the invention can remove not only a large amount of endogenous and exogenous lipocytoviruses, but also non-lipocytoviruses. The method of the invention is not only effective for inactivating more complex carbohydrate-modified cytokine-type proteins, but also can keep the protein activity of the recombinant human thrombopoietin at a higher level without affecting the quality of finished products.
Description
Technical Field
The invention belongs to the field of biological preparations, and relates to a method for removing and/or inactivating viruses in recombinant human thrombopoietin (PAF) stock solution.
Background
In the last 50 th century, kelemen et al discovered and proposed that a humoral factor capable of stimulating the production of platelets in blood existed in vivo, and named Thrombopoietin (TPO), which has a significant effect of promoting the development and maturation of the megakaryocyte system. Recombinant human thrombopoietin (rh-TPO) is a recombinant glycoprotein containing 332 amino acids and expressed by CHO engineering bacteria, and can regulate the growth, differentiation, maturation and division of megakaryocytes to form functional platelets by binding with a specific receptor Mpl, and can be used for treating severe thrombocytopenia and Idiopathic Thrombocytopenic Purpura (ITP) caused by solid tumor and acute leukemia radiotherapy and chemotherapy, bone marrow transplantation, aplasia and other bone marrow insufficiency, HIV and the like.
In the process of preparing the recombinant human thrombopoietin by using CHO engineering bacteria, virus inactivation is required. The existing virus inactivation process mainly has the following modes in blood products and monoclonal antibodies:
1. pasteurization: the method is suitable for a stable albumin inactivation process, and is mature for inactivating HIV and hepatitis viruses.
2. Dry heat method (lyophilized formulation): the virus such as HCV, HBV, HIV and HAV can be inactivated by heating at 80 deg.C for 72 hr, but the water content and content of the product should be considered to influence the inactivation of virus.
3. Low pH inactivation incubation method: several lipolytics can be inactivated at low pH (e.g., pH = 4) in immunoglobulin production under conditions that take into account pH, incubation time, temperature, solution solute, and the like.
4. The membrane filtration method comprises the following steps: the method is only used for filtering under the condition that the effective diameter of a filter membrane is smaller than that of viruses, and the method cannot be used alone and needs to be combined with other methods for use.
The virus inactivation processes of the 1 st, the 2 nd and the 4 th methods are mainly suitable for blood preparations, and the monoclonal antibody is mainly suitable for the combined use of the 3 rd and the 4 th methods.
At present, for recombinant human thrombopoietin type products, glycosylation accounts for a high percentage, accounting for about 30% of the molecular size, and compared with monoclonal antibodies, no mature virus inactivation method exists at present due to complex glycosylation modification sites and glycoforms, unstable proteins and the like. For example, the domestic rh-TPO product mainly has peculiar smell of sheng yang, sansheng, and is produced and marketed in 2006, and in view of the previous regulations and the condition limitations such as industry cognition degree, protein complexity and the like, the product cannot inactivate and remove potential viruses and does not meet the requirements at the present stage. Furthermore, the prior art does not mention the inactivation and treatment of potential viruses on cytokine products with complex glycosylation and unstable protein, which causes great risk and hidden danger to the drug safety.
Thus, there is a need for a method for removing and/or inactivating viruses from a stock solution of recombinant human thrombopoietin.
Disclosure of Invention
Based on the deficiencies of the prior art, it is an object of the present invention to provide a method for removing and/or inactivating viruses from a stock solution of recombinant human thrombopoietin. The method provided by the invention has simple steps, solves the problems of the adipocyte membrane virus and the non-adipocyte membrane virus which can not be removed by using the traditional method, such as porcine virus, bovine virus and the like, and has important significance for the production and the use of the recombinant human thrombopoietic factor.
In one aspect, the present invention provides a method for removing and/or inactivating virus from a recombinant human thrombopoietin stock solution, the method comprising:
inactivating virus by using a fermentation liquor of recombinant human thrombopoietin (rh-TPO) by using an S/D method; and
the purified fermentation broth was filtered using a nanomembrane to remove viruses.
The method of the invention, wherein the reagents used in the S/D method are tributyl phosphate and triton-100;
wherein the working concentration of the tributyl phosphate is 0.3% + -0.03% (v/v), and the working concentration of the triton-100 is 1% + -0.1% (v/v).
The method of the invention, wherein the inactivation condition of the S/D method is as follows: treating with S/D reagent at 23-27 deg.c for at least 1 hr.
Preferably, the conditions for inactivation by the S/D method are as follows: at 25 ℃ the treatment was carried out for 4 hours using S/D reagent.
Preferably, the nanomembrane filtration is performed using a ViresolvePro virus removal filtration membrane from Millipore corporation.
The method according to the invention comprises the following steps:
1) Culturing engineering cells of recombinant human platelet-derived factor (rh-TPO) to obtain fermentation liquor;
2) Inactivating viruses of the fermentation liquor by using an S/D method;
3) Purifying the fermentation liquor inactivated by an S/D method;
4) Filtering the purified fermentation liquor by using a nano membrane to obtain the nano-composite.
The method according to the present invention, wherein, in step 3), the purification is cation chromatography, hydrophobic chromatography, and anion chromatography in this order.
The method according to the present invention, wherein the method further comprises the step of sterile filtration and/or dispensing.
The applicant finds that in the preparation of the recombinant human thrombopoietin stock solution, the traditional process is used for virus inactivation, so that lipid cell membrane viruses and non-lipid cell membrane viruses, such as porcine viruses, bovine viruses and the like, cannot be removed, the use risk and the medication safety of patients are greatly increased, and the requirements of the current pharmaceutical industry specifications are not met. Therefore, it is necessary to add the inactivation process of lipid enveloped virus and non-lipid enveloped virus in the preparation process, thereby greatly reducing the huge risk caused by incomplete virus inactivation. The inventor actively explores and researches the inactivation mode of the potential virus in the rH-TPO cytokine production process according to related monoclonal antibody inactivation processes and blood product inactivation processes at home and abroad and related legal and regulatory requirements, and finally completes the blank field of virus removal and inactivation with complex glycosylation modification of cytokines and unstable protein activity through a large amount of experimental investigation. The method of the invention can remove a large amount of endogenous and exogenous lipid cell membrane viruses, can also remove non-lipid cell membrane viruses, can simultaneously maintain the protein activity with higher degree and the lowest S/D inactivator residue, and plays a great role in the medication safety of patients.
The invention solves the problem of inactivation mode of potential viruses in the production process of recombinant cytokine products, finally completes the blank field of ineffective virus inactivation/virus removal in the production process with relatively complex glycosylation modification and unstable protein activity through a large amount of experiments, and has a certain guiding function on virus removal and inactivation in the future production process of cytokine products.
Compared with the prior art, the method provided by the invention has the following advantages:
1. the method of the invention can remove not only a large amount of endogenous and exogenous lipid cell membrane viruses, but also non-lipid cell membrane viruses.
2. The method of the invention is not only effective in inactivating more complex proteins of the sugar-modified cytokines, but also can keep the protein activity of the recombinant human thrombopoietin at a higher level without affecting the quality of finished products.
3. By using the method of the invention, S/D residues can be almost completely removed by carrying out ion exchange chromatography separation subsequently, so that the product meets the standard requirement of no harm to human bodies, and plays a great role in the medication safety of patients.
4. The method of the invention solves the blank that the cytokine products can not inactivate the potential viruses, and has important production and practical significance.
Drawings
Embodiments of the invention are described in detail below with reference to the attached drawing figures, wherein:
FIG. 1 is an HPLC chromatogram of rh-TPO stock after inactivation using the S/D method in example 1 according to the present invention;
FIG. 2 is a SDS PAGE result of rh-TPO stock after inactivation using S/D method in example 1 according to the present invention;
FIG. 3 is a SDS PAGE result of rh-TPO stock after inactivation using low pH incubation in comparative example 1 according to the present invention;
FIG. 4 is an HPLC profile of a sample after inactivation using low pH incubation according to comparative example 1 of the present invention, before low pH inactivation, as shown in method 1 by hydrophobic chromatography;
FIG. 5 is an HPLC plot of samples subjected to low pH inactivation by hydrophobic chromatography as described in method 1 after inactivation by low pH incubation in comparative example 1 according to the present invention;
FIG. 6 is an HPLC plot of the sample after inactivation using low pH incubation of comparative example 1 according to the present invention, prior to low pH inactivation of the sample by anion chromatography as described in method 2;
FIG. 7 is an HPLC chromatogram of a sample subjected to low pH inactivation by anion chromatography as shown in method 2 after inactivation by low pH incubation in comparative example 1 according to the present invention;
FIG. 8 is a SDS PAGE result of rh-TPO stock after inactivation of the fermentation broth using low pH incubation in comparative example 2 according to the present invention.
Detailed Description
Example 1 inactivation of Lipocytic Membrane Virus Using the method of the invention
In this example, the lipid membrane of enveloped viruses was disrupted mainly with an organic solvent/detergent mixture (S/D) to achieve an effective inactivation of lipid enveloped viruses.
1.1 Experimental methods
First, the procedure for preparing rh-TPO stock solution in this example is as follows:
1) Culturing rh-TPO engineering cells;
2) Sequentially carrying out cation chromatography, hydrophobic chromatography and anion chromatography on the fermentation liquor;
wherein, cation chromatography is carried out by using a composite weak cation medium MMC Diamond;
hydrophobic chromatography was performed using Butyl HP packing;
anion chromatography was performed using a MixA Mustang ion exchange packing;
3) Sterilizing, filtering and/or packaging.
Based on the fact that S/D reagent is an organic reagent and detergent is a relatively hydrophobic substance, S/D inactivation is not suitable to be placed before the hydrophobic chromatography process, the applicant has studied placing S/D inactivation between the hydrophobic chromatography process and the anion chromatography Mustang process or the fermentation broth step to test.
The method comprises the following steps: using 0.3% phosphoric acidInactivation of 1% Tributine-100
Subjecting the fermentation liquor to hydrophobic chromatography, sampling 50mL of the pilot-scale hydrophobic chromatography, adding 150 muL of TNBP and 0.5mL of Triton X100 to enable the final volume concentration to be 0.3% and 1%, stirring uniformly, and inactivating for 1h. The solution was a white turbid solution, which was filtered through a 0.45 μm membrane, and the solution was still turbid.
The method 2 comprises the following steps: inactivation of 0.3% tributyl phosphate 1% Tween 80
Subjecting the fermentation liquor to hydrophobic chromatography, sampling 50mL of the hydrophobic chromatography sample of a pilot plant, adding 150 μ L of tributyl phosphate, 0.5mL of Tween 80, stirring uniformly to make the final volume concentration of the tributyl phosphate and the final volume concentration of the Tween 80 respectively 0.3% and 1%, and inactivating for 1h.
Control 3: the blank is not inactivated
Samples from method 1, method 2 and control 3 were subjected to anion chromatography, procedure: flow rate 0.7mL/min liquid A balance → loading → liquid A wash 3CV → 11% by weight B wash 4CV → 50% by weight B wash 5CV, and collect the eluate.
1.2 analysis of results:
1.2.1 HPLC profileThe results of the HPLC experiments of the above two methods and the control are shown in FIG. 1, wherein FIG. 1 is a spectrum of a sample after an anion chromatography Mustang step.
The method comprises the following steps: 0.3% TNBP 1 inactivation by Triton X100, elution harvest volume 6.4mL;
the method 2 comprises the following steps: 0.3% TNBP 1% inactivation Tween 80, elution Collection volume 9.2mL;
comparison 3: blank was not inactivated and elution was collected in a volume of 6.2mL.
It can be seen from the figure that the samples without inactivation of method 1 and control 3 blanks have very similar peak appearance time, peak area and purity in the HPLC liquid phase, and the method 1 protocol is feasible.
1.2.2 SDS
PAGE results:
the results of SDS PAGE for the above two methods and controls are shown in FIG. 2, in which 1-10 are shown as follows: 1. the loading solution of control 3; 2. flow-through for control 3; 3. eluent of control 3; 4. the sample loading solution of the method 1; 5. flow-through of method 1; 6. the eluent of method 1; 7. the sample loading solution of the method 2; 8. flow-through of method 2; 9. the eluent of method 2; 10. mark-Marker;
as can be seen from the electropherogram,
1) The inactivation by the S/D method has no influence on the sample preparation by the hydrophobic chromatography, the rh-TPO strip is not degraded,
2) The selected S/D inactivation conditions are as follows: inactivating 0.3% tributyl phosphate and 1% triton-100 for 1h at normal temperature; as can be seen from the experimental pattern, the elution of the blank 3 was almost identical to the SDAPAGE band of method 1 (i.e., using 0.3% tributyl phosphate 1% triton-100), and the volume collected by elution was substantially identical; as can also be seen from SDS PAGE, there was no flow-through in both method 1 and control 3, and the eluted rh-TPO band was substantially the same. In method 2, after inactivation by 0.3% tributyl phosphate and tween-80, the target protein showed a lower yield.
Therefore, the inactivation condition adopted by the method is an S/D (S/D) inactivator, namely 0.3 percent of tributyl phosphate and 1 percent of triton-100 are inactivated for 1 hour, and the method can be suitable for inactivating rh-TPO protein at normal temperature.
1.2.3 And (3) S/D inactivation effect verification:
the S/D inactivation effect is verified by adopting indicative viruses designated by a hospital inspection, two indicative viruses of VSV (vesicular stomatitis virus)/PRV (pseudorabies virus) are adopted to verify the inactivation effect, and the inactivation capacity of the rh-TPO agent stock solution (20161118, 20161119 and 20161220) is basically up to more than 4log TCID50/0.1mL for PRV or VSV through S/D inactivation results, and most of the inactivated viruses can be completely inactivated after being homogenized for 1 hour. As can be seen, inactivation using the S/D method of the present invention completely inactivated adipocyte membrane virus.
Since the purpose of this example was to optimize the inactivation step, the inventors found that by locating the inactivation step on the front end of the purification process, tributyl phosphate and triton-100, impurities introduced can be removed by both cationic and hydrophobic chromatography. Meanwhile, certain potential viruses can be further removed by the corresponding chromatographic packing. Thus, S/D inactivation of lipocytoviruses is carried out in cell culture broth.
Example 2 inactivation of non-adipocyte Membrane Virus Using the method of the invention
The purpose of this example is to add a nano-membrane filtration step to remove non-lipid membrane viruses, based on the removal of lipid membrane viruses,the Pro series nanofiltration membrane is made of double-layer polyether sulfone material, so that high-level virus removal can be realized, and the Log removal rate of the virus is more than or equal to 4Log.
In example 1, after the chromatography step, viresolvePro virucidal filtration membrane from millipore was selected to perform virucidal filtration pilot protein load experiments.
Purpose of the experiment: protein load was calculated by needle-type virus filtration membrane removal.
The experimental process comprises the following steps: a viral nanofiltration system was assembled using a peristaltic pump and nanofiltration membranes, and the batch (protein concentration 0.425 mg/mL) was filtered, nanofiltration membrane model:pro Micro Device; membrane area: 3.1cm 2 (ii) a Setting the filtering pressure to be 0.15-0.2MPa, weighing the filtrate every minute, calculating the flow rate change according to the weighing result, determining the full loading capacity of the filtering membrane when the filtering flow rate is reduced to 80% of the initial flow rate, calculating the protein loading capacity at the moment, and calculating the specification of the filtering membrane required by the production scale.
TABLE 1 data weight per minute summary Unit (g)
From the analysis of the results, it can be seen from the above table that the nanofiltration rate drops to below 80% of the initial rate at filtration time to 22 minutes, i.e., protein loading is reached at 22 minutes.
And (3) calculating:
filter membrane loading =0.425mg/mL × 88.9mL ÷ 3.1cm 2 =12.19mg/cm 2
When the fermentation is carried out in large-scale batch according to 100L, the total protein of the nano-membrane filtration stage is about 1600mg, so the total area of the required nano-membrane is 1600mg/12.19/cm 2 =140cm 2
EXAMPLE 3 detection analysis of residual Effect of S/D:
The related TNBP and Triton residues need to meet the requirements of the latest pharmacopoeia, for which the applicant has performed the viral inactivation of three batches (20161118, 20161119 and 20161220) of rh-TPO stock solutions, respectively, using the method of the present invention and examined the residual effect of S/D in the final product, the results are shown in the following table:
TABLE 2 detection of residual amount of S/D inactivator
As can be seen from the table, the method of the present invention has the lowest S/D inactivator residue, and plays a great role in the safe administration of patients.
Comparative example 1 virus was inactivated using low pH incubation and nanomembrane filtration:
low pH incubation: generally, the pH value of the solution is controlled to be below 3.8, and the solution can be inactivated for 2 hours, so that several lipid enveloped viruses can be inactivated. The stability of the target protein pH3.8 was first determined for each chromatography step as follows:
3.1 purpose of the experiment
Comparing the cation chromatography MMC sample, the hydrophobic chromatography Butyl HP sample and the anion MixA sample, adjusting the pH value to 3.8 for inactivation, and confirming the inactivation process steps.
3.2 Experimental methods
First, the procedure for preparing a rh-TPO stock solution in this comparative example was as follows:
1) Culturing rh-TPO engineering cells;
2) Sequentially carrying out cation chromatography, hydrophobic chromatography and anion chromatography on the fermentation liquor
Wherein, cation chromatography is carried out by using a composite weak cation medium MMC Diamond;
hydrophobic chromatography was performed using Butyl HP packing;
anion chromatography was performed using a MixAMustang ion exchange packing;
3) Sterilizing, filtering and/or packaging.
The method comprises the following steps:
and (2) performing MMC and hydrophobic chromatography on fermentation liquor, wherein 42mL of eluent, pH 6.94, cond:11.81ms/cm, adjusted pH3.8 with 1M HAC, added slowly and added with a magnetic stirrer in an amount of 3.5mL pH3.80, maintained for 2h adjusted pH 7.0 with 1M Tris-HCl pH 9.0 in an amount of 4mL, measured Cond:13.10 (Mustang for anion chromatography can load directly), and HPLC is measured;
the method 2 comprises the following steps:
taking 50mL of fermentation liquor after MMC, hydrophobic chromatography and anion chromatography, adjusting pH to 3.8 by 1M HAC at pH 6.98, slowly adding the fermentation liquor and a magnetic stirrer at the dosage of 4mL and pH3.80, maintaining for 2 hours, adjusting pH to 7.0 by 1M Tris-HCl pH 9.0 at the dosage of 4.25mL, and measuring HPLC;
the method 3 comprises the following steps:
taking a fermentation liquid, loading 38mL of pH 8.16 by cation chromatography MMC Diamond, adjusting the pH to 3.8 by using 1M HAC, slowly adding the mixture, adding the mixture by using a magnetic stirrer, keeping the pH at 6.5mL of pH3.80, and keeping the mixture for 2 hours; 30mL of the sample was subjected to electrophoresis with 6mL of 1M Tris-HCl pH 9.0 to adjust pH 7.0.
3.3 analysis of results:
3.3.1 SDS
PAGE results
The results of SDS-PAGE electrophoresis of the above three methods are shown in FIG. 3, wherein 1-9 in the electrophoresis are shown respectively:
1 is MMC sample (not inactivated at 4 ℃ for 48 h);
2 MMC sample (25 ℃ room temperature 20h without inactivation);
3 is MMC sample (after pH inactivation);
4 is butyl HP sample (not inactivated at 4 ℃ for 48 h);
5 is butyl HP load (25 ℃ room temperature 20h without inactivation);
6 is butyl HP sample (after pH inactivation);
7 is Mix A Mustang sample (not inactivated at 4 ℃ for 48 h);
8. mix a Mustang load (25 ℃ room temperature 20h without inactivation;
9. mix a Mustang (after pH inactivation);
wherein, the 3 rd, 6 th and 9 th bands are samples after low pH inactivation, compared with the samples without inactivation, the protein is degraded and does not meet the quality requirement.
3.3.2 HPLC profile
The results of HPLC chromatography of the above three methods are shown in FIGS. 4-7 and tables 3-6, wherein FIGS. 4 and 3 are the HPLC profile and results of the hydrophobic chromatography sample before low pH inactivation as shown in method 1; before inactivation: HPLC purity 85.32%. Wherein FIG. 5 and Table 4 are HPLC profiles and results of hydrophobic chromatography samples after low pH inactivation as shown in method 1; after inactivation: the main peak retention time was from 14.73min to 15.81min, indicating that the target had degraded. FIG. 6 and Table 5 are HPLC profiles and results of anion chromatography samples prior to low pH inactivation as shown in method 2; before inactivation: the purity is 98.97%; FIG. 7 and Table 6 show the HPLC profile and results of the anion chromatography inactivation at low pH for the anion chromatography sample, pH3.8 for the anion chromatography sample, purity: 89.08 percent.
TABLE 3
TABLE 4
TABLE 5
TABLE 6
And (3) analysis:
1) Low pH inactivation: MMC and Butyl samples are unstable at low pH inactivation, which is not suitable after MMC and Butyl.
2) The purity of the liquid phase of the sample subjected to low-pH inactivation by anion chromatography is reduced from 98.97% to 89.08%, the purity is reduced by 7%, and polymers are generated, and the sample subjected to anion chromatography is not suitable for low-pH inactivation.
Comparative example 2 virus inactivation using low pH incubation at fermentation broth stage:
after the fermentation broth is inactivated by low pH, purification is started to prepare a sample for analysis:
a cation chromatography step:
column: BXK 50/30h: 360mL N/m:4913AS:1.86
Buffer A:20mM PB pH 6.50.1M NaCl Buffer B:20mM PB pH 6.5 1M NaCl
Buffer C:50mM Tris pH 8.01M NH4Cl 2M Urea
Sample treatment: adjusting pH of 2L fermentation liquid to 3.8 with 1M HAC, adjusting pH to 6.5 with 1M Tris after 2h at room temperature, and filtering with 1 μ M filter to obtain 3.3L sample.
The process is as follows: 0.5M NaOH treatment → purified water → liquid a balance → loading 25mL/min,2.9L (1.75L fermentation broth) → liquid a washing → liquid B washing → liquid C elution → purified water → 0.5M NaOH regeneration;
a hydrophobic chromatography step:
column: BXK 26/20h:14cm
Buffer A:20mM PB 0.8M AS pH 7.0 cond
Buffer B20mM PB, pH 7.0
Sample preparation: 450mL of the sample was subjected to cation chromatography, adjusted to pH 7.0 with HCl and Cond with 3M ammonium sulfate: and 100ms/cm is the sample.
The process is as follows: 0.5M NaOH treatment → purified water → liquid A balance → sample application 8mL/min → liquid A washing → liquid B elution → purified water → 0.5M NaOH regeneration
3.5 Analysis of the SDS PAGE results:
the result of SDS-PAGE electrophoresis in this method is shown in FIG. 8, in which 1-10 of the electrophoresis are shown separately
1. Fermentation liquor
2. MMC flow-through is finished
3. MMC flow-through liquid mixed sample 4 and MMC impurity washing first peak
5. Second peak of MMC washing
6. MMC eluted protein peaks of interest
7. butyl HP flow peak-crossing
8. butyl HP Wash miscellaneous peaks
9. Butyl HP eluted the peaks of interest
10、Marker
Analysis and conclusion:
1) Compared with the prior purification process, the peak height of the AKTA preparation map is twice lower than that of the small test process; hydrophobic chromatography E1 is also more than doubled lower than the pilot process.
2) SDS PAGE detection results: no significant TPO band was observed for MMC elution, nor was hydrophobic chromatography elution observed, and all protein degradation.
3) Low pH inactivation is also not suitable when placed on fermentation broth.
In conclusion, the conventional low pH incubation method is not suitable for virus inactivation in the rhTPO recombinant protein production process.
Although the present invention has been described to a certain extent, it is apparent that appropriate changes in the respective conditions may be made without departing from the spirit and scope of the present invention. It is to be understood that the invention is not limited to the described embodiments, but is to be accorded the scope consistent with the claims, including equivalents of each element described.
Claims (7)
1. A method for removing and/or inactivating virus from a recombinant human thrombopoietin stock solution, the method comprising:
inactivating viruses in fermentation liquor of the recombinant human thrombopoietic factor by using an S/D method; and
filtering the purified fermentation broth using a nanomembrane to remove viruses,
wherein the reagents used in the S/D method are tributyl phosphate and triton-100;
the purification is sequentially cation chromatography, hydrophobic chromatography and anion chromatography.
2. The method of claim 1, wherein the working concentration of tributyl phosphate is 0.3% ± 0.03% (v/v) and the working concentration of triton-100 is 1% ± 0.1% (v/v).
3. The method of claim 1, wherein the S/D method inactivation is: treating with S/D reagent at 23-27 deg.c for at least 1 hr.
4. The method of claim 3, wherein the conditions for S/D inactivation are: the treatment was carried out at 25 ℃ for 4 hours using S/D reagent.
5. The method of claim 1, wherein the nanomembrane is a Viresolve Pro virus removal filtration membrane.
6. The method according to any one of claims 1-5, comprising the steps of:
1) Culturing engineering cells of the recombinant human platelet-derived factor to obtain fermentation liquor;
2) Inactivating viruses of the fermentation liquor by using an S/D method;
3) Purifying the fermentation liquor inactivated by an S/D method;
4) Filtering the purified fermentation liquor by using a nano membrane to obtain the nano-composite.
7. The method of claim 6, wherein the method further comprises the step of sterile filtering and/or dispensing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910837015.6A CN110590931B (en) | 2019-09-05 | 2019-09-05 | Method for removing and/or inactivating virus in recombinant human thrombopoietin stock solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910837015.6A CN110590931B (en) | 2019-09-05 | 2019-09-05 | Method for removing and/or inactivating virus in recombinant human thrombopoietin stock solution |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110590931A CN110590931A (en) | 2019-12-20 |
CN110590931B true CN110590931B (en) | 2023-04-07 |
Family
ID=68857642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910837015.6A Active CN110590931B (en) | 2019-09-05 | 2019-09-05 | Method for removing and/or inactivating virus in recombinant human thrombopoietin stock solution |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110590931B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110627892B (en) * | 2019-09-05 | 2023-04-14 | 江苏康禾生物制药有限公司 | Preparation method of recombinant human thrombopoietic factor stock solution |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408861A (en) * | 2001-09-19 | 2003-04-09 | 上海中信国健药业有限公司 | Recombination human platelet producing factor cDNA sequence and its use |
WO2005082937A2 (en) * | 2004-02-27 | 2005-09-09 | Octapharma Ag | A method of providing a purified, virus safe antibody preparation |
CN1752102A (en) * | 2005-09-05 | 2006-03-29 | 武汉海特生物制药股份有限公司 | Technology of preparing rat nerve growth factor using organic solvent virus deactivation method |
KR100791502B1 (en) * | 2006-09-29 | 2008-01-03 | 한스바이오메드 주식회사 | Production methods of virus inactivated and cell-free body implant |
CN109943554A (en) * | 2017-12-21 | 2019-06-28 | 舒泰神(北京)生物制药股份有限公司 | A method of extracting factor X activator from snake venom |
CN110627892A (en) * | 2019-09-05 | 2019-12-31 | 江苏康禾生物制药有限公司 | Preparation method of recombinant human thrombopoietic factor stock solution |
-
2019
- 2019-09-05 CN CN201910837015.6A patent/CN110590931B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408861A (en) * | 2001-09-19 | 2003-04-09 | 上海中信国健药业有限公司 | Recombination human platelet producing factor cDNA sequence and its use |
WO2005082937A2 (en) * | 2004-02-27 | 2005-09-09 | Octapharma Ag | A method of providing a purified, virus safe antibody preparation |
CN1752102A (en) * | 2005-09-05 | 2006-03-29 | 武汉海特生物制药股份有限公司 | Technology of preparing rat nerve growth factor using organic solvent virus deactivation method |
KR100791502B1 (en) * | 2006-09-29 | 2008-01-03 | 한스바이오메드 주식회사 | Production methods of virus inactivated and cell-free body implant |
CN109943554A (en) * | 2017-12-21 | 2019-06-28 | 舒泰神(北京)生物制药股份有限公司 | A method of extracting factor X activator from snake venom |
CN110627892A (en) * | 2019-09-05 | 2019-12-31 | 江苏康禾生物制药有限公司 | Preparation method of recombinant human thrombopoietic factor stock solution |
Non-Patent Citations (2)
Title |
---|
"Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII";Peter L.Roberts;《Biologicals》;20080801;第36卷(第5期);第330-335页 * |
"血液制剂中的TNBP/去污剂处理";韩建军;《国外医学.输血及血液学分册》;19880229;第11卷(第1期);第86-87页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110590931A (en) | 2019-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4342828A (en) | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells | |
CA2192683C (en) | Filtration | |
DE69127384T2 (en) | Process for the purification of immune serum globulins | |
JP2018503620A (en) | Methods for purifying recombinant proteins | |
CN102532307B (en) | Method for preparing human immunoglobulin | |
CN106146660B (en) | Method for separating and purifying monoclonal antibody | |
CN107163138B (en) | Separation and purification method of human plasma protein alpha 1-antitrypsin | |
DE3786832T2 (en) | Process for the preparation of immunoglobulin preparations for intravenous injection. | |
CN110590931B (en) | Method for removing and/or inactivating virus in recombinant human thrombopoietin stock solution | |
CN114181300A (en) | Preparation method of high-purity monoclonal antibody | |
EP2655397B1 (en) | Method for extracting human serum albumin from transgenic rice grain | |
CN109320611B (en) | Purification method of human-mouse chimeric monoclonal antibody biological similar drug | |
CN116410294A (en) | Preparation and purification method of monopolyethylene glycol recombinant human erythropoietin | |
CN113121637B (en) | Separation and purification method of recombinant protein | |
CN107188952A (en) | A kind of purification process of recombinant human granulocyte colony stimulating factor | |
TW201416372A (en) | Caprylate viral deactivation | |
CN112500477B (en) | Method for rapidly extracting human immunoglobulin from blood plasma | |
CN110872345B (en) | Preparation method of high-purity immunoglobulin G | |
CN113880908B (en) | Method for purifying fusion protein of recombinant human serum albumin | |
CN113584106B (en) | Preparation method and application of recombinant novel coronavirus NCP-RBD protein expressed by CHO (Chinese hamster ovary) cells | |
AU2004228847B2 (en) | Process for producing albumin preparation | |
JPH08787B2 (en) | Method for producing composition containing gamma globulin | |
CN113717281B (en) | Buffer solution for affinity chromatography for removing anti-A and anti-A hemagglutinin in intravenous injection human immunoglobulin and application thereof | |
CN118063587A (en) | Technological method for reducing recombinant human granulocyte stimulating factor precursor associated protein content | |
RU2163140C1 (en) | Concentrate of factor ix of blood coagulation system and method of its preparing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |